Literature DB >> 24048678

Liver biopsy for parenchymal liver disease - is routine real time image guidance unnecessary?

Anil John1, Saad Al Kaabi, Madiha Emran Soofi, Muneera Mohannadi, Salva Manam Kandath, Moataz Derbala, Rafie Yakoub, Esra Mohammed Al-Ahdal, Manik Sharma, Hamid Wani, Nazeeh Dweik, Anjum John, Mohammed Tariq Butt.   

Abstract

Liver biopsy even today remains the standard of care for grading and staging chronic hepatitis despite advances in noninvasive markers of liver fibrosis. Literature suggests an expanding role for real-time image guided liver biopsy and declining trend for blind liver biopsies. In our center, where we perform around 400 liver biopsies per year, we performed a prospective clinical audit of our practice of blind outpatient percutaneous liver biopsies. Patients requiring histological grading and staging of chronic hepatitis routinely undergo blind outpatient percutaneous liver biopsies in our endoscopy unit unless there is a definite indication for real-time image guidance. All procedures were assessed for safety, and all specimens were evaluated by a specimen quality grading score for adequacy for grading and staging of chronic hepatitis. Of the 446 patients referred for histological grading and staging of chronic hepatitis C by liver biopsy, only 42 patients (9.5 %) required real-time ultrasound for liver biopsy. The remaining 404 patients underwent blind outpatient percutaneous liver biopsies which were found to be extremely safe with no major complications, yielding adequate liver tissue with high specimen quality score allowing optimal grading and staging of chronic hepatitis.

Entities:  

Mesh:

Year:  2013        PMID: 24048678     DOI: 10.1007/s12664-013-0393-3

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  18 in total

1.  Percutaneous liver biopsy: what is the current approach? Results of a questionnaire survey.

Authors:  W Mayoral; J H Lewis
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

2.  Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology.

Authors:  A Grant; J Neuberger
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 3.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

4.  Liver biopsy size matters in chronic hepatitis: bigger is better.

Authors:  Peter J Scheuer
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

5.  Audit of state-funded antiviral treatment for chronic hepatitis C in Qatar.

Authors:  A K John; Kaabi S Al; A John; R Singh; M Derbala
Journal:  East Mediterr Health J       Date:  2010-11       Impact factor: 1.628

6.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  A 21-year experience with major hemorrhage after percutaneous liver biopsy.

Authors:  D B McGill; J Rakela; A R Zinsmeister; B J Ott
Journal:  Gastroenterology       Date:  1990-11       Impact factor: 22.682

8.  Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs.

Authors:  R J Farrell; P F Smiddy; R M Pilkington; A A Tobin; E E Mooney; I J Temperley; G S McDonald; H A Bowmer; G F Wilson; D Kelleher
Journal:  J Hepatol       Date:  1999-04       Impact factor: 25.083

9.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.

Authors:  Guido Colloredo; Maria Guido; Aurelio Sonzogni; Gioacchino Leandro
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

10.  Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists.

Authors:  Terence L Angtuaco; Sunil K Lal; Geraldine D Banaad-Omiotek; Syed S A Zaidi; Colin W Howden
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

View more
  2 in total

1.  Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing.

Authors:  Manik Sharma; Saad Al Kaabi; Anil K John; Nazeeh Al Dweik; Hameed Ullah Wani; Ragesh Babu Thandassary; Moutaz F Derbala; Khalid Al Ejji; Khaleel Sultan; Fuad Pasic; Munnera Al Mohannadi; Rafae Yacoub; Mohd Tariq Butt; Rajvir Singh
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

2.  A single-center experience: Liver biopsy results during a year.

Authors:  Cenk Emre Meral; Genco Gencdal; Murat Akyildiz; Fulya Gunsar; Deniz Nart; Funda Yilmaz; Zeki Karasu; Galip Ersoz; Ulus Salih Akarca
Journal:  Hepatol Forum       Date:  2022-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.